Directorio

We are doing this study to learn more about the olfactory receptor expression (which give us our sense of smell) and neurogenesis (creation of cells) in human olfactory tissue.

We are doing this study to improve how cancer patients and their providers communicate with each other. We want to know how personal biases can affect how cancer care is explained and managed. We think being able to identify bias if any exists can improve care and patients' psychological well-being.

We are doing this study to improve how patients and their primary care providers can keep up with routine health maintenance during cancer treatments. We want to know if a new model of communication between patients and their doctors can improve health outcomes.

We are doing this study to compare activity in the brains of female adults who have chronic pain and/or use opioids to the brain activity of healthy female adults who are pain-free. We hope this study can help us develop new and targeted treatments for adults with chronic pain and alternatives to opioid therapy.

We are doing this study to find the most effective, safe dose of an experimental drug called linvoseltamab (the study drug) compared to a combination of three cancer drugs(elotuzumab, pomalidomide, and dexamethasone) for people who have multiple myeloma.

We are doing this study to find out if an experimental drug called ORIC-114 (the study drug) is a safe and effective option for possible treatment in patients with advanced solid tumors harboring an EGFR or HER2 alteration.

We are doing this study to find out if an experimental drug called axitinib (the study drug) is a safe and effective option for people with neovascular age-related macular degeneration (nAMD). The study drug is given to people using a developing technology called the Ocular Therapeutix Intravitreal Implant (OTX-TKI).

We are doing this study to learn more about the effects of the prescription drug Oxbryta (voxelotor) on sickle cell disease (SCD) when it is prescribed to patients. We want to keep track of the health of people with SCD who take this drug as part of their normal care.